Dear Sir, The discouraging results provided by dietary and behavioural treatments, and the virtually non-existent drug treatments, have led to an exponential increase in use of surgery to treat obesity 1. An increased prevalence of obesity has also been reported in patients with acromegaly, a rare and severe systemic disease caused by a growth hormone (GH)-secreting pituitary adenoma, compared to the general population 2. In obesity, GH responses to a wide variety of GH secretion stimulators, as well as 24 h spontaneous GH release are decreased, making difficult acromegaly follow-up. Moreover, insulin-like growth factor-1 (IGF-1), which mediates some of the metabolic actions of GH, is reported to be decreased in obesity and negatively correlated to visceral fat 3. To the best of our knowledge, we report the first case of a patient with acromegaly who underwent bariatric surgery and we describe the biochemical effects associated with the resolution of obesity and its comorbidities.
展开▼
